Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Resonance SpecialtiesBOM:524218 +4.99%66 Cyclically Adjusted PS Ratio is 2.49 as of Sep. 08, 2026, which is 35% above its 10-year median of 1.85. GuruFocus rates BOM:524218 with a GF Score™ of 66/100 and a GF Value™ of ₹159.60 (Fairly Valued). The stock has 7 warning signs investors should review. Among 1,273 Chemicals companies, Resonance Specialties ranks worse than 68.26% on this metric.
The historical rank and industry rank for Resonance Specialties's Cyclically Adjusted PS Ratio or its related term are showing as below:
BOM:524218'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.94 Med: 1.85 Max: 4.47
Current: 2.37
During the past years, Resonance Specialties's highest Cyclically Adjusted PS Ratio was 4.47. The lowest was 0.94. And the median was 1.85.
BOM:524218's Cyclically Adjusted PS Ratio is ranked worse than 68.26% of 1273
companies
in the Chemicals industry
Industry Median: 1.34
vs BOM:524218: 2.37
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Resonance Specialties's adjusted revenue per share data for the three months ended in Jun. 2026 was ₹28.248. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹68.00 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Resonance Specialties (BOM:524218) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Resonance Specialties Cyclically Adjusted PS Ratio Related Terms
Resonance Specialties Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Resonance Specialties's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Specialties Cyclically Adjusted PS Ratio Chart
BOM:524218 vs DOW: Cyclically Adjusted PS Ratio Comparison
For the Chemicals subindustry, Resonance Specialties's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Specialties Cyclically Adjusted PS Ratio vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Resonance Specialties's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Resonance Specialties's Cyclically Adjusted PS Ratio falls into.
Resonance Specialties Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 2.49 mean?
Resonance Specialties (BOM:524218) has a Cyclically Adjusted PS Ratio of 2.49 as of Sep. 08, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Resonance Specialties and its competitors. This is 35% above median its historical median of 1.85. Over the past decade, Resonance Specialties' Cyclically Adjusted PS Ratio has ranged from 0.94 to 4.47. According to the industry distribution chart, Resonance Specialties ranks #869 out of 1273 companies in the Chemicals industry, placing it in the top 68.3%.
Is Resonance Specialties' Cyclically Adjusted PS Ratio too high?
Resonance Specialties' current Cyclically Adjusted PS Ratio of 2.49 is 35% above median its 10-year median of 1.85. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 4.47. The Chemicals industry median Cyclically Adjusted PS Ratio is 1.34. Resonance Specialties' value of 2.49 is 85.8% above this industry median. Based on the distribution chart, Resonance Specialties ranks #869 out of 1273 companies in the Chemicals industry, which is below the industry midpoint. Overall, Resonance Specialties has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Resonance Specialties' Cyclically Adjusted PS Ratio compare to DOW?
According to the Chemicals industry distribution chart, Resonance Specialties ranks #869 out of 1273 companies for Cyclically Adjusted PS Ratio. This places Resonance Specialties in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 1.34. Resonance Specialties' value of 2.49 is 85.8% above this benchmark. Historically, Resonance Specialties' own Cyclically Adjusted PS Ratio has ranged from 0.94 to 4.47 over the past decade. While the company's 10-year median is 1.85 vs. the industry median of 1.34, Resonance Specialties has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Chemicals company?
The median Cyclically Adjusted PS Ratio among Chemicals companies is 1.34, based on 1,273 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Specialties's current Cyclically Adjusted PS Ratio of 2.49 is 85.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Resonance Specialties and its competitors. For the Chemicals industry, the median Cyclically Adjusted PS Ratio is 1.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Specialties's current Cyclically Adjusted PS Ratio is 2.49, which is 35% above median its own 10-year median of 1.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Specialties stock overvalued right now?
Based on GuruFocus' analysis, Resonance Specialties (BOM:524218) is currently considered Fairly Valued. The stock's GF Value™ is ₹159.60, compared to a current price of ₹169.45 — trading 6.2% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 2.49, which is 35% above median its 10-year median of 1.85 and 85.8% above the Chemicals industry median of 1.34. Resonance Specialties' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Resonance Specialties (BOM:524218), the current Cyclically Adjusted PS Ratio is 2.49 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Resonance Specialties (BOM:524218) Overvalued in 2026?
Based on GuruFocus' analysis, Resonance Specialties stock appears to be overvalued.
The current stock price of ₹169.45 is trading 6.2% above its estimated GF Value™ of ₹159.60.
GuruFocus considers Resonance Specialties to be Fairly Valued.
Key valuation signals for BOM:524218:
Cyclically Adjusted PS Ratio: 2.49 (35% above median its 10-year median of 1.85)
GF Value™: ₹159.60 vs. price of ₹169.45 (6.2% above fair value)
Industry Position: 85.8% above the Chemicals median (#869 of 1273)
No single metric tells the full story. See the BOM:524218 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Resonance Specialties Ltd is engaged in the manufacturing of chemicals. The company is manufacturing Pyridine, Picoline, Cynopyridine, and derivatives of the same. Bulk drugs and nutritional products are tolls converted. It delivers pyridine and related products. The company has only one segment which is Chemical Manufacturing. The company also manufactures anti-tuberculosis products such as Isoniazid. Geographically. It operates in India and Outside India. The majority of segment revenue is from Outside India.
66GF Score
Get the complete analysis for BOM:524218
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524218 has been successfully added to your 
